Ellen de Brabander - Mar 1, 2024 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Executive Vice President of Innovation and Regulatory Affairs
Signature
/s/ Amy C. Seidel, as Attorney-in-Fact for Ellen de Brabander
Stock symbol
ELAN
Transactions as of
Mar 1, 2024
Transactions value $
-$156,677
Form type
4
Date filed
3/5/2024, 04:25 PM
Previous filing
Mar 1, 2024
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Award $0 +31.8K +34.31% $0.00 125K Mar 1, 2024 Direct F1
transaction ELAN Common Stock Tax liability -$157K -9.77K -7.84% $16.03 115K Mar 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option(right to buy) Award $0 +69.5K $0.00 69.5K Mar 1, 2024 Common Stock 69.5K $16.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2024, one-third vesting on March 1, 2025, one-third vesting on March 1, 2026, and the remaining vesting on March 1, 2027.
F2 Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
F3 Grant of stock options vesting as follows: one-third vesting on March 1, 2025, one-third vesting on March 1, 2026, and the remaining vesting on March 1, 2027.

Remarks:

Executive Vice President of Innovation and Regulatory Affairs